TABLE 4.

Multivariable Analysis for Subgroups With Significant Differences Among Treatment Regimens

T4 or N3 HPV+ OPSCC	HR (95% CI)	P	Global P
Distant Metastasis
RT regimen			.030
CCRT	Reference
RT‐hypo	1.67 (0.44‐6.30)	.450
RT‐acc	2.61 (1.28‐5.31)	.008
Age			.440
≤70 y	Reference
>70 y	1.36 (0.62‐3.01)
Smoking status			.100
None/ex‐smoker	Reference
Current smoker	1.70 (0.90‐3.21)

Stage III HPV– HNSCC	HR (95% CI)	P	Global P
Locoregional Failure
RT regimen			.011
CCRT	Reference
RT‐hypo	3.40 (1.05‐10.99)	.041
RT‐acc	4.89 (1.69‐14.14)	.003
Age			.690
≤70 y	Reference
>70 y	0.88 (0.45‐1.69)
Smoking status			.180
None/ex‐smoker	Reference
Current smoker	0.65 (0.35‐1.23)

Stage III Laryngeal SCC	HR (95% CI)	P	Global P
Locoregional Failure
RT regimen			.004
CCRT	Reference
RT‐hypo	3.90 (0.76‐19.98)	.100
RT‐acc	8.95 (2.15‐37.26)	.003
Age			.230
≤70 y	Reference
>70 y	0.60 (0.26‐1.37)
Smoking status			.710
None/ex‐smoker	Reference
Current smoker	0.86 (0.39‐1.91)

Abbreviations: CCRT, concurrent chemoradiotherapy; HNSCC, head and neck squamous cell carcinoma; HPV, human papillomavirus; HR, hazard ratio; OPSCC, oropharyngeal squamous cell carcinoma; RT, radiotherapy; RT‐acc, moderately accelerated radiotherapy; RT‐hypo, hypofractionated radiotherapy; SCC, squamous cell carcinoma. Bold values denote statistical significance at the p <0.05 level.